Undercoagulation was common in AF patients who suffered from stroke and impacts outcome

5-4-2017 • Xian Y et L., JAMA. 2017
In a contemporary registry, 84% of patients with a history of AF received no or subtherapeutic anticoagulation, which affected severity of stroke and in-hospital mortality. Read more
News • 31-3-2017

What’s the new evidence base for heart failure diagnosis & management?

EPCCS 2017 Impression of the lecture at the EPCCS CV Summit, given by professor Arno Hoes (Utrecht, The Netherlands). Read more
News • 31-3-2017

Controversies in Lipids – is the role of statins now clear, are there alternatives, and what’s in the pipeline?

EPCCS 2017 Impression of the special invited lecture at the EPCCS CV Summit, given by Professor John Chapman (Paris, France). Read more
News • 30-3-2017

Guidance on changing health behaviours – what is the evidence, what’s recommended, and do I agree?

EPCCS 2017 Impression of the lecture at the EPCCS CV Summit, given by Professor Christi Deaton (Cambridge, UK). Read more
News • 30-3-2017

Live from #EPCCS2017 CV Summit: call for active GP participation

Dublin During the EPCCS CV Summit a pre-session was dedicated to discuss how the European network of GPs with a special interest in CV medicine can be strengthened and how EPCCS can contribute to this process. Read more

Number of major cardiovascular events lower with ARBs than with ACEi

28-3-2017 • Potier L, et al, Heart 2017
Rate of major cardiovascular events was lower in high cardiovascular risk outpatients of the REACH registry on ARBs compared to these on ACEi, particularly in those with established atherosclerosis.   Read more
News • 4-4-2017

Fish oil supplementation can benefit some, but not all, CV conditions

The AHA has updated their 2002 Scientific Statement on the use of omega-3 PUFA supplementation in primary and secondary prevention of various CV conditions. Read more
News • 31-3-2017

What do the 2016 ESC guidelines on atrial fibrillation say and what are the implications for primary care?

EPCCS 2017 Impression of the lecture at the EPCCS CV Summit, given by dr. Geert-Jan Geersing (Utrecht, The Netherlands). Read more
News • 31-3-2017

What do the 2016 ESC Guidelines on cardiovascular risk and elevated lipids say and what are the implications for primary care?

EPCCS 2017 Impression of the lecture at the EPCCS CV Summit, given by dr Carlos Brotons (Barcelona, Spain). Read more
News • 30-3-2017

Controversies in Hypertension – what are the implications of SPRINT in the context of recent treatment trials?

EPCCS 2017 Impression of the special invited lecture at the EPCCS CV Summit, given by Professor Richard McManus (Oxford, UK). Read more

Very low LDL-C levels are safe and effective in high-risk post-ACS patients

29-3-2017 • Giugliano RP, et al. JAMA Cardiol. 2017
LDL-C levels <30 mg/dL at 1 month were associated with a similar safety profile and with numerical reductions in CV events compared with higher LDL-C levels in high-risk post-ACS patients. Read more

Gastrointestinal safety profiles differ among direct oral anticoagulants

28-3-2017 • Abraham NS, et al, Gastroenterology 2017
In a large population-based cohort of AF patients on DOACs, apixaban had most favourable gastrointestinal safety profile among all age groups, and rivaroxaban the least favourable.  Read more

Upcoming meetings

Meeting reports & resources

EPCCS Guidance Documents Evidence- and meeting-based guidance for primary care
EPCCS 2015 Report of 8th Annual EPCCS meeting held in Prague.
EPCCS 2014 Report of 7th Annual EPCCS meeting held in Brussels.
EPCCS 2013 Report of 6th Annual EPCCS meeting held in London
All meeting reports...